Tag Archives: pain

Targeted Medical Pharma Combats the Epidemic of Pain with Release of THERALEVE™

Los Angeles, — Targeted Medical Pharma, Inc. (OTCQB: TRGM) in conjunction with Amino Nutritionals LLC, today announced the consumer release of THERALEVE™ (www.theralevehealth.com) a patented amino acid based formula designed by pain management physicians to help the 100 million chronic pain sufferers in the United States, fight pain and inflammation without the dangerous side effects commonly associated with NSAIDs and opioids. “Common pain medications do not address the nutritional needs of the nervous system and only target symptoms of pain. THERALEVE provides a specific blend Continue reading →

TARGETED MEDICAL PHARMA BREAKS GROUND IN THE CONSUMER GOODS MARKET

Targeted Medical Pharma, Inc. (OTCQB: TRGM), announced the establishment of a new subsidiary, Amino Nutritionals LLC, that will specialize in the development and marketing of THERALEVE™, a proprietary consumer product for chronic pain sufferers to be sold in the United States and abroad. The Company is pleased to announce the hiring of Joshua Levine as the Vice President of Direct Consumer Sales. Mr. Levine will spearhead the direct marketing efforts for Amino Nutritionals, and will be responsible for building the infrastructure required for market development Continue reading →

Research Identifies a Potential New Path to Developing a Treatment for Chronic Pain

Los Angeles, September 8, 2015 – Targeted Medical Pharma to present new chronic pain research that reveals significant nervous system abnormalities among patients suffering from Fibromyalgia, at the 2015 PainWeek national conference in Las Vegas, Nevada. The study looked at 329 Fibromyalgia patients and 58 control patients all of whom wore Holter monitors for a 24 hour period to measure nervous system activity. The results of this study showed that patients with Fibromyalgia experience a significant decrease in both nighttime parasympathetic nervous system (PNS) activity and daytime sympathetic Continue reading →

Targeted Medical Pharma Announces New Partnership for Exclusive Distribution in Japan

Los Angeles, February 19,  2015 – Targeted Medical Pharma (OTCQB: TRGM), today announced the completion of an exclusive product distribution agreement with J-Network Inc., a  California-based company that specializes in distributing cosmetic and healthcare goods exclusively to Japan. The Agreement grants J-Network an exclusive one-year renewable license for the marketing and sales of the Company’s proprietary product, designed to improve sleep and immune function, in Japan. Under the terms of the Agreement, Targeted Medical Pharma will develop new products specific for import into the Japanese Continue reading →

Targeted Medical Pharma’s New Approach to Pain Management Targets Epidemic of Opioid and NSAID Over-Prescribing

White Paper explores Theramine® as a Safe and Clinically Effective Alternative to Common Pain Medications  Los Angeles, CA, October 6, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), recently published the White Paper: Innovations in Pain Management discussing the epidemic of pain, the dangers of commonly prescribed pain medications and the benefits of Theramine, as a clinically effective alternative to opioids and nonsteroidal anti-inflammatory (NSAID) drugs for the management of back pain and inflammation. According to Consumer Reports, the overuse of opioid pain medications has reached epidemic Continue reading →

Clinical Trial Results Confirm Amino Acid Based Medical Food Theramine® More Effective at Improving Chronic Back Pain than NSAID Pain Medications

Los Angeles, CA, September  23, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) a drug discovery and development company, announced the results of a second, double-blind clinical trial which confirmed that Theramine was shown not only to be more effective than ibuprofen in reducing low back pain, but also demonstrated a significant reduction in measures of inflammation. In this 28 day, multi-center trial, subjects taking Theramine as either a standalone medication or in conjunction with a low dose ibuprofen, demonstrated a significant reduction in both Continue reading →

Targeted Medical Pharma to Present at Sachs Associated 14th Annual Biotech in Europe Forum for Global Partnering and Investment

Los Angeles, September 16, 2014 — Targeted Medical Pharma (OTCQB:TRGM), today announced that William Shell, M.D., Chairman, CSO and CEO  is scheduled to present the latest company information regarding the advances in therapeutic nutrition and medical foods technology, at the 14th Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. The presentation is scheduled for September 30th, 2014 at 11:45 am in the Lima Room. Dr. Shell will also be a panelist in the discussion regarding advancements in Neuroscience at 3:30 pm. Additional information Continue reading →

Targeted Medical Pharma Appoints Two New Independent Members to the Board of Directors

 Health Care Veteran Kerry Weems and Corporate Finance Expert Paul Pelosi, Jr. Join the Advisory Team Los Angeles, CA, June 13, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the addition of two independent members to the Company’s board of directors. The Company welcomes back health care specialist Kerry Weems to the board as an independent director and chairman of the Nominating and Governance Committee, as well as corporate finance expert Paul Pelosi, Jr. as an independent director. A nationally respected expert in Continue reading →

Targeted Medical Pharma to Present at the Third Annual Marcum MicroCap Conference

Los Angeles, CA –  May 23, 2014 – Targeted Medical Pharma (OTCQB: TRGM), a leader in the medical food manufacturing sector, announced today that it will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel. The Company’s presentation by William Shell M.D., Chief Executive Officer and Chief Science Officer, is scheduled to begin at 11:30 a.m. ET. The annual Marcum MicroCap Conference is a signature showcase for superior quality, Continue reading →

Healthcare Executive Dr. Thomas Wenkart Joins Targeted Medical Pharma’s Board of Directors

Los Angeles, March 10, 2014 –Targeted Medical Pharma, Inc. (OTCQB:TRGM) today announced that Dr. Thomas Wenkart, Chief Executive and Chairman at Macquarie Health Corporation, has joined the company’s board of directors. A nationally respected expert in healthcare, medical and hospital administration in Australia, Dr. Wenkart established Macquarie Health Corporation in Sydney, Australia in 1976. His organization owns and operates eleven private hospitals in Australia, and is one of the nation’s leading providers of healthcare services. Dr. Wenkart is a graduate of the Sydney University School Continue reading →